tiprankstipranks
Teva Pharmaceutical (GB:0LER)
LSE:0LER
UK Market
0LER
Teva Pharmaceutical
RESEARCH TOOLSreports

Teva Pharmaceutical (0LER) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0LER Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Teva
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0LER Stock 12 Month Forecast

Average Price Target

$41.50
▲(19.08% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Teva Pharmaceutical in the last 3 months. The average price target is $41.50 with a high forecast of $44.00 and a low forecast of $40.00. The average price target represents a 19.08% change from the last price of $34.85.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","30":"$30","45":"$45","22.5":"$22.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,22.5,30,37.5,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.497,36.15107692307692,36.80515384615384,37.45923076923077,38.11330769230769,38.767384615384614,39.421461538461536,40.075538461538464,40.729615384615386,41.38369230769231,42.03776923076923,42.69184615384616,43.34592307692308,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.497,35.95876923076923,36.42053846153846,36.88230769230769,37.344076923076926,37.805846153846154,38.26761538461538,38.72938461538462,39.191153846153846,39.652923076923074,40.11469230769231,40.57646153846154,41.03823076923077,{"y":41.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.497,35.843384615384615,36.18976923076923,36.536153846153844,36.88253846153846,37.228923076923074,37.57530769230769,37.92169230769231,38.268076923076926,38.61446153846154,38.960846153846155,39.30723076923077,39.653615384615385,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.385,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.945,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.413,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.238,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.496,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.658,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.828,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.852,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.463,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.947,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.466,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.497,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$44.00Average Price Target$41.50Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0LER
David Amsellem
Piper Sandler
Piper Sandler
$44
Buy
26.26%
Upside
Reiterated
08/27/26
Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
Barclays Analyst forecast on GB:0LER
Glen Santangelo
Barclays
Barclays
$40→$42
Buy
20.52%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)
UBS Analyst forecast on GB:0LER
Ashwani Verma
UBS
UBS
$42
Buy
20.52%
Upside
Reiterated
08/07/26
Teva: Buy Rating Reiterated as Analyst Sees Listing and Pipeline Upside, Keeps $42 Price Target Unchanged
Bank of America Securities Analyst forecast on GB:0LER
Jason Gerberry
Bank of America Securities
Bank of America Securities
$40→$41
Buy
17.65%
Upside
Reiterated
07/30/26
Analysts Are Bullish on These Healthcare Stocks: Option Care Health (OPCH), Teva Pharmaceutical (TEVA)
Scotiabank Analyst forecast on GB:0LER
Louise Chen
Scotiabank
Scotiabank
$40
Buy
14.78%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NYSE: NVST), Teva Pharmaceutical (NYSE: TEVA) and MannKind (NASDAQ: MNKD)
Jefferies Analyst forecast on GB:0LER
Dennis Ding
Jefferies
Jefferies
$40
Buy
14.78%
Upside
Reiterated
07/10/26
Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
J.P. Morgan Analyst forecast on GB:0LER
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Ionis Pharmaceuticals (NASDAQ: IONS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Goldman Sachs Analyst forecast on GB:0LER
Matthew Dellatorre
Goldman Sachs
Goldman Sachs
$45→$50
Buy
43.47%
Upside
Reiterated
04/30/26
Teva price target raised to $50 from $45 at Goldman SachsTeva price target raised to $50 from $45 at Goldman Sachs
Truist Financial Analyst forecast on GB:0LER
Les Sulewski
Truist Financial
Truist Financial
$42→$45
Buy
29.12%
Upside
Assigned
04/30/26
Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
Evercore ISI Analyst forecast on GB:0LER
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
11/26/25
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)
Guggenheim Analyst forecast on GB:0LER
Yatin Suneja
Guggenheim
Guggenheim
―
Hold
―
Reiterated
11/18/25
Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (NYSE: TEVA) and Purple Biotech (NASDAQ: PPBT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0LER
David Amsellem
Piper Sandler
Piper Sandler
$44
Buy
26.26%
Upside
Reiterated
08/27/26
Piper Sandler Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
Barclays Analyst forecast on GB:0LER
Glen Santangelo
Barclays
Barclays
$40→$42
Buy
20.52%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), AbbVie (NYSE: ABBV) and Legend Biotech (NASDAQ: LEGN)
UBS Analyst forecast on GB:0LER
Ashwani Verma
UBS
UBS
$42
Buy
20.52%
Upside
Reiterated
08/07/26
Teva: Buy Rating Reiterated as Analyst Sees Listing and Pipeline Upside, Keeps $42 Price Target Unchanged
Bank of America Securities Analyst forecast on GB:0LER
Jason Gerberry
Bank of America Securities
Bank of America Securities
$40→$41
Buy
17.65%
Upside
Reiterated
07/30/26
Analysts Are Bullish on These Healthcare Stocks: Option Care Health (OPCH), Teva Pharmaceutical (TEVA)
Scotiabank Analyst forecast on GB:0LER
Louise Chen
Scotiabank
Scotiabank
$40
Buy
14.78%
Upside
Reiterated
07/30/26
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NYSE: NVST), Teva Pharmaceutical (NYSE: TEVA) and MannKind (NASDAQ: MNKD)
Jefferies Analyst forecast on GB:0LER
Dennis Ding
Jefferies
Jefferies
$40
Buy
14.78%
Upside
Reiterated
07/10/26
Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
J.P. Morgan Analyst forecast on GB:0LER
Chris Schott
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Ionis Pharmaceuticals (NASDAQ: IONS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Goldman Sachs Analyst forecast on GB:0LER
Matthew Dellatorre
Goldman Sachs
Goldman Sachs
$45→$50
Buy
43.47%
Upside
Reiterated
04/30/26
Teva price target raised to $50 from $45 at Goldman SachsTeva price target raised to $50 from $45 at Goldman Sachs
Truist Financial Analyst forecast on GB:0LER
Les Sulewski
Truist Financial
Truist Financial
$42→$45
Buy
29.12%
Upside
Assigned
04/30/26
Teva Upgraded to $45 Price Target on Strong Execution, Emalex Acquisition, and Growing Neurology Pipeline Upside
Evercore ISI Analyst forecast on GB:0LER
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
11/26/25
Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)
Guggenheim Analyst forecast on GB:0LER
Yatin Suneja
Guggenheim
Guggenheim
―
Hold
―
Reiterated
11/18/25
Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (NYSE: TEVA) and Purple Biotech (NASDAQ: PPBT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Teva Pharmaceutical

3 Months
Glen SantangeloBarclays
Success Rate
9/12 ratings generated profit
75%
Average Return
+10.66%
Copying Glen Santangelo's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +10.66% per trade.
1 Year
Glen SantangeloBarclays
Success Rate
12/12 ratings generated profit
100%
Average Return
+22.98%
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.98% per trade.
2 Years
Jason GerberryBank of America Securities
Success Rate
31/31 ratings generated profit
100%
Average Return
+95.51%
Copying Jason Gerberry's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +95.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0LER Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
23
20
20
19
21
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
20
20
19
21
In the current month, 0LER has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0LER average Analyst price target in the past 3 months is 41.50.
Each month's total comprises the sum of three months' worth of ratings.

0LER Financial Forecast

0LER Earnings Forecast

Next quarter’s earnings estimate for 0LER is $0.71 with a range of $0.60 to $0.74. The previous quarter’s EPS was $0.02. 0LER beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0LER has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0LER is $0.71 with a range of $0.60 to $0.74. The previous quarter’s EPS was $0.02. 0LER beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0LER has Performed in-line its overall industry.

0LER Sales Forecast

Next quarter’s sales forecast for 0LER is $4.23B with a range of $4.05B to $4.37B. The previous quarter’s sales results were $4.22B. 0LER beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0LER has Performed in-line its overall industry.
Next quarter’s sales forecast for 0LER is $4.23B with a range of $4.05B to $4.37B. The previous quarter’s sales results were $4.22B. 0LER beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0LER has Performed in-line its overall industry.

0LER Stock Forecast FAQ

What is GB:0LER’s average 12-month price target, according to analysts?
Based on analyst ratings, Teva Pharmaceutical’s 12-month average price target is 41.50.
    What is GB:0LER’s upside potential, based on the analysts’ average price target?
    Teva Pharmaceutical has 19.08% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Teva Pharmaceutical a Buy, Sell or Hold?
          Teva Pharmaceutical has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Teva Pharmaceutical’s share price target?
            The average share price target for Teva Pharmaceutical is 41.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $44.00 ,and the lowest forecast is $40.00. The average share price target represents 19.08% Increase from the current price of $34.85.
              What do analysts say about Teva Pharmaceutical?
              Teva Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Teva Pharmaceutical?
                To buy shares of GB:0LER, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.